TY - JOUR
T1 - Time-restricted feeding normalizes hyperinsulinemia to inhibit breast cancer in obese postmenopausal mouse models
AU - Das, Manasi
AU - Ellies, Lesley G.
AU - Kumar, Deepak
AU - Sauceda, Consuelo
AU - Oberg, Alexis
AU - Gross, Emilie
AU - Mandt, Tyler
AU - Newton, Isabel G.
AU - Kaur, Mehak
AU - Sears, Dorothy D.
AU - Webster, Nicholas J.G.
N1 - Funding Information:
We thank histology and microscopy cores at the Moores UCSD Cancer Center for their assistance. Funding: this work was supported by National Institutes of Health grants CA196853, CA155435, CA023100, VA Merit Review grants I01BX002709 and I01BX004848, and a VA Senior Research Career Scientist IK6BX005224 award. The data that support the findings of this study are available from the corresponding author upon reasonable request. Copyright-free cartoon images were obtained from pub-licdomainvectors.org.
Publisher Copyright:
© 2021, This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may applyor(s).
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Accumulating evidence indicates that obesity with its associated metabolic dysregulation, including hyperinsulinemia and aberrant circadian rhythms, increases the risk for a variety of cancers including postmenopausal breast cancer. Caloric restriction can ameliorate the harmful metabolic effects of obesity and inhibit cancer progression but is difficult to implement and maintain outside of the clinic. In this study, we aim to test a time-restricted feeding (TRF) approach on mouse models of obesity-driven postmenopausal breast cancer. We show that TRF abrogates the obesity-enhanced mammary tumor growth in two orthotopic models in the absence of calorie restriction or weight loss. TRF also reduces breast cancer metastasis to the lung. Furthermore, TRF delays tumor initiation in a transgenic model of mammary tumorigenesis prior to the onset of obesity. Notably, TRF increases whole-body insulin sensitivity, reduces hyperinsulinemia, restores diurnal gene expression rhythms in the tumor, and attenuates tumor growth and insulin signaling. Importantly, inhibition of insulin secretion with diazoxide mimics TRF whereas artificial elevation of insulin through insulin pumps implantation reverses the effect of TRF, suggesting that TRF acts through modulating hyperinsulinemia. Our data suggest that TRF is likely to be effective in breast cancer prevention and therapy.
AB - Accumulating evidence indicates that obesity with its associated metabolic dysregulation, including hyperinsulinemia and aberrant circadian rhythms, increases the risk for a variety of cancers including postmenopausal breast cancer. Caloric restriction can ameliorate the harmful metabolic effects of obesity and inhibit cancer progression but is difficult to implement and maintain outside of the clinic. In this study, we aim to test a time-restricted feeding (TRF) approach on mouse models of obesity-driven postmenopausal breast cancer. We show that TRF abrogates the obesity-enhanced mammary tumor growth in two orthotopic models in the absence of calorie restriction or weight loss. TRF also reduces breast cancer metastasis to the lung. Furthermore, TRF delays tumor initiation in a transgenic model of mammary tumorigenesis prior to the onset of obesity. Notably, TRF increases whole-body insulin sensitivity, reduces hyperinsulinemia, restores diurnal gene expression rhythms in the tumor, and attenuates tumor growth and insulin signaling. Importantly, inhibition of insulin secretion with diazoxide mimics TRF whereas artificial elevation of insulin through insulin pumps implantation reverses the effect of TRF, suggesting that TRF acts through modulating hyperinsulinemia. Our data suggest that TRF is likely to be effective in breast cancer prevention and therapy.
UR - http://www.scopus.com/inward/record.url?scp=85099828523&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099828523&partnerID=8YFLogxK
U2 - 10.1038/s41467-020-20743-7
DO - 10.1038/s41467-020-20743-7
M3 - Article
C2 - 33495474
AN - SCOPUS:85099828523
SN - 2041-1723
VL - 12
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 565
ER -